The I-SPY COVID Adaptive Platform Trial for COVID-19 Acute Respiratory Failure: Rationale, Design and Operations

Data Availability

The trial procedures and protocols are regulated under a central IRB structure at the Wake Forest School of Medicine. All patients (or designated surrogate) entering the portion of the trial that receive an investigational agent undergo patient level consent by study staff and/or study investigators. Protocol revisions are announced at weekly investigator and coordinator meetings and are submitted to the FDA and IRB. No patient level data will be released, and all personal information will remain confidential and de-identified. Results of the agents completing the ISPY COVID Trial will be reported in press releases, scientific abstracts and manuscripts.